Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has scheduled a Board Meeting on November 02, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has issued a confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has updated on ongoing litigation under Regulation 30 of SEBI (LODR), 2015, disclosing a development in relation to the Customs, Excise & Service Tax Appellate Tribunal (CESTAT) case. The Tribunal has upheld the Company's entitlement to refund of accumulated CENVAT credit along with interest, amounting to Rs. 2751 Lakhs.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half year ended September 30, 2026.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has filed an application with the stock exchanges seeking reclassification from the 'Promoter Group' category to 'Public' category, as per SEBI regulations.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has published unaudited financial results for the first quarter ended June 30, 2026, in the Financial Express newspaper.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd held its 21st Annual General Meeting on August 10, 2026, through video conferencing, where all resolutions were passed with a requisite majority. The meeting saw the appointment of Mr. Anil Kumar Raghavan as the Managing Director and Chief Executive Officer of the company.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has submitted a monitoring agency report for the quarter ended June 30, 2026, regarding the utilization of proceeds from a preferential issue of convertible warrants. The report by Acuité Ratings & Research Limited states that there are no deviations from the objects of the issue.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹3,992 lakhs and other income at ₹1,84,002 lakhs. The company's board of directors has approved the results and the reclassification of certain promoter group individuals.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd announced the outcome of its board meeting, approving unaudited financial results for the quarter ended June 30, 2026, and reclassifying certain promoter group individuals from the 'Promoter Group' category to the 'Public' category.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 10/08/2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd has received requests from two shareholders, Sudhir Vrundavandas Valia and his family members, to reclassify their status from 'Promoter Group' to 'Public' category under SEBI regulations.